In situ expression of CD40 and CD40 ligand in psoriasis

被引:32
|
作者
Ohta, Y
Hamada, Y
机构
[1] Yokohama Natl Univ, Fac Div Dermatol, Yokohama, Kanagawa 240, Japan
[2] Kitasato Univ, Sch Med, Dept Dermatol, Sagamihara, Kanagawa 228, Japan
关键词
psoriasis; CD40; ligand; immunohistochemistry;
D O I
10.1159/000078582
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The interaction between CD40 and CD40 ligand (CD40L) provides a signal that contributes to the initiation of cellular immune responses. However, little information on the in vivo expression of CD40 and CD40L in cutaneous inflammation has been reported. Objective: To investigate the potential role of CD40-mediated signals in the pathogenesis of psoriasis. Materials and Methods: In situ CD40 and CD40L expression was examined immunohistochemically in different stages of psoriatic lesions: fully developed and initial pinpoint. Results: In normal skin, faintly positive immunoreactivity for CD40 was seen in the basal keratinocytes and dermal endothelial cells. These showed almost the same intensity as that seen in psoriatic lesional skin. In the dermal infiltrates of psoriatic lesions, CD40 was intensely expressed and some of these positive cells appeared to be dendritic in shape. Whereas CD40 expression was observed almost in all specimens of psoriatic lesions, the expression of CD40L was predominantly detected in the initial pinpoint lesions of psoriasis. These seemed to be distributed close to CD40-positive cells. Conclusion: These results suggested that CD40L-triggered signals could be involved in the early stage of psoriatic lesion formation. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:21 / 28
页数:8
相关论文
共 50 条
  • [21] Maintained CD40 and loss of polarised CD40 ligand expression in oral squamous cell carcinoma
    Loro, LL
    Ohlsson, M
    Vintermyr, OK
    Viavaag, PG
    Jonsson, R
    Johannessen, AC
    ANTICANCER RESEARCH, 2001, 21 (1A) : 113 - 117
  • [22] Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment
    Liu, MF
    Chao, SC
    Wang, CR
    Lei, HY
    AUTOIMMUNITY, 2001, 34 (02) : 107 - 113
  • [23] Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia
    Garlichs, CD
    John, S
    Schmeisser, A
    Eskafi, S
    Stumpf, C
    Karl, M
    Goppelt-Struebe, M
    Schmieder, R
    Daniel, WG
    CIRCULATION, 2001, 104 (20) : 2395 - 2400
  • [24] CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders
    Younes, A
    Carbone, A
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1999, 14 (03): : 135 - 143
  • [25] The role of CD40/CD40 ligand interactions in the expression of OX40 ligand and 4.1 BB ligand in antigen presenting cells
    Schneider, N.
    Muller, C.
    Barabas, S.
    Lindner, J.
    Altmann, D.
    Wolf, W.
    Schblmerich, J.
    Fleck, M.
    Demi, L.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 46 - 46
  • [26] Short treatment with atorvastatin lowers platelet CD40 ligand expression and soluble CD40 ligand in hypercholesterolemic patients
    Sanguigni, V
    Pignatelli, P
    Ferro, D
    Bellia, A
    Lenti, L
    Tesauro, M
    Lauro, R
    Violi, F
    EUROPEAN HEART JOURNAL, 2004, 25 : 49 - 50
  • [27] THE INFLUENCE OF CD40/CD40 LIGAND ON THE PROGNOSIS OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
    Patiroglu, T.
    Unal, E.
    Karakukcu, M.
    Mutlu, F. T.
    Ozdemir, M. A.
    HAEMATOLOGICA, 2012, 97 : 493 - 494
  • [28] CD154 (CD40 ligand)
    Schönbeck, U
    Mach, F
    Libby, P
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2000, 32 (07): : 687 - 693
  • [29] Regulation of CD40 and CD40 ligand by the AT-hook transcription factor AKNA
    Aisha Siddiqa
    Jennifer C. Sims-Mourtada
    Liliana Guzman-Rojas
    Roberto Rangel
    Christiane Guret
    Vicente Madrid-Marina
    Yan Sun
    Hector Martinez-Valdez
    Nature, 2001, 410 : 383 - 387
  • [30] Soluble CD40 as a modulator of CD40 pathway
    Esposito, Pasquale
    Rampino, Teresa
    Dal Canton, Antonio
    IMMUNOLOGY LETTERS, 2012, 147 (1-2) : 85 - 86